Record Full-Year Revenue
Full-year 2025 revenue of $830.5 million, up 19.3% versus 2024 and well above initial guidance.
Record Consolidated Adjusted EBITDA and Margin Expansion
Consolidated adjusted EBITDA of $116.2 million, up 21.3% year-over-year, with consolidated adjusted EBITDA margin of 14.0% (180 basis points improvement since 2022).
Strong Organic Growth and Long-Term Track Record
Organic revenue growth of 12.7% in 2025 (well above the 7%–9% long-term target) and roughly 20% revenue CAGR from 2020–2025, driven by ~13% average annual organic growth.
Exceptional Cash Generation and Conversion
Operating cash flow of $107 million in 2025, representing 93% conversion of consolidated adjusted EBITDA; record free cash flow of $87 million (75% of consolidated adjusted EBITDA).
Strong Balance Sheet and Liquidity
Leverage ratio improved to 2.5x (below 3x target), $225 million of available liquidity, and full redemption of $122 million Series A-2 preferred six months ahead of schedule, eliminating future preferred dividends.
2026 Guidance and Margin Targeting
2026 guidance: revenue $840M–$900M and consolidated adjusted EBITDA $125M–$130M (midpoint ≈10% EBITDA growth); company targets ~15% consolidated adjusted EBITDA margin for 2026 and expects high end of 7%–9% organic growth range.
Cross-Selling and Commercial Momentum
Percentage of revenue from cross-selling increased from 53% to 62%, and management highlighted conversion of emergency response engagements into longer-term remediation and consulting work.
Segment Strength: Assessment, Permitting & Response
Assessment, Permitting & Response segment revenue grew 43% to $307.4 million; segment adjusted EBITDA increased to $68.5 million (22.3% margin).
Segment Strength: Measurement & Analysis Margin Expansion
Measurement & Analysis revenue grew 9.6% to $245.9 million; segment adjusted EBITDA improved to $64.4 million with margin expansion of 370 basis points to 26.2%.
Strategic Capital Allocation Enabled
Completed balance sheet simplification enabling: initiation of a $40 million share repurchase authorization, planned 1%–2% of revenue investment in proprietary technology/R&D, and measured return to accretive M&A (focused on small, bolt-on deals).